ILI Reports On Annual Stockholder Meeting And Announces New Director
06/14/2006
INTERLEUKIN GENETICS REPORTS ON ANNUAL STOCKHOLDER MEETING AND ANNOUNCES NEW DIRECTOR
Waltham, MA, June 14, 2006 - Interleukin Genetics (AMEX: ILI) today reported results of its Annual Meeting of Stockholders and the appointment of a new member to the Company’s Board of Directors. During its Annual Meeting, Stockholders of the Company ratified the election of Grant Thornton LLP as the Company’s auditors. Additionally, Interleukin today announced that Dianne E. Bennett was appointed as a member of the Board of Directors of Interleukin and will serve on the audit, compensation and nominating committees of the Board of Directors. Ms. Bennett succeeds William J. Viveen, Jr., as a member of the Interleukin Board of Directors. Both Ms. Bennett and Mr. Viveen were elected by Interleukin’s strategic corporate partner, Alticor Inc.
“Alticor continues to be a great partner for commercialization of our DNA-based risk assessment tests that promote wellness and personalized health,” commented Kenneth Kornman, DDS, PhD, President and CEO of Interleukin Genetics. “We welcome Ms. Bennett to the Interleukin Board and look forward to her contributions to the future success of the Company. We sincerely thank Bill Viveen for his contributions to Interleukin and wish him the best in his future endeavors.”
Dianne E. Bennett is the Director of Administration of Alticor Inc., a company engaged in the principle business, through its affiliates, of offering products, business opportunities, and manufacturing and logistics services in more than 80 countries and territories worldwide. Ms. Bennett has been an employee of the Alticor family of companies for over 25 years in positions that include Supervisor of Internal Audit, Manager of International Finance, Manager of Affiliate Support, Sr. Manager of Corporate/North American Accounting and Director of the Program Management Office. Ms. Bennett holds a Bachelor’s degree in Accounting from Aquinas College and a Master’s in Business Administration from Western Michigan University. She is a CPA and member of the American Institute of Certified Public Accountants.
About Interleukin
Interleukin Genetics is a biotechnology company focused on developing and commercializing personalized health products. The company uses functional genomics to help in the development of risk assessment tests, pharmacogenetic tests, nutritional and therapeutic products based on the genetic variations in people. Interleukin Genetics has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment, and its current development programs focus on osteoporosis, and weight management. Interleukin expects that these programs will also lead to products that will personalize the selection of nutritional and therapeutic products and enable the managed care industry to improve patient care and better allocate resources. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com .
Certain statements contained herein are “forward-looking” statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns, our ability to construct a DNA testing laboratory, our ability to complete all of our key milestones with regard to Alticor programs, our ability to make progress in advancing our core technologies and our ability to launch new commercial products and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2005 filed with the Securities and Exchange Commission, our quarterly reports on Form 10-Q and in other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
For Interleukin Genetics:
Janet Perry
(781) 398-0700